Samsung Epis Holdings, the parent company of leading biosimilar drug developer Samsung Bioepis, announced its strategic establishment of a new research and development (R&D) center in China. This move signifies a major step in bolstering its advanced drug development capabilities globally.
The innovative biotech firm has recently launched a wholly-owned subsidiary, Samsung Bioepis China, located in Beijing’s prominent Changping district. This marks a significant milestone as their inaugural overseas R&D foothold, strategically positioned for global innovation.
Established in November, Samsung Epis Holdings underscores that the creation of this cutting-edge China R&D center reflects the company’s strong commitment to advancing critical antibody-drug conjugate (ADC) platform technologies and driving the development of next-generation biopharmaceutical drugs.
Strategically situated in Changping, the new R&D center benefits from being at the heart of the Zhongguancun Life Science Park, a leading biotech cluster in China. Samsung Epis Holdings emphasizes that this prime location provides unparalleled access to a robust research ecosystem and an exceptional talent pool, thanks to its proximity to prestigious institutions like Peking University and Tsinghua University.
The official opening of the Samsung Bioepis China R&D Center is anticipated in June. It is designed to function as a highly specialized local research organization, leveraging the expertise of talented staff members exclusively recruited within China.
Kim Kyung-ah, CEO of Samsung Epis Holdings, stated, “The establishment of our China R&D center is a clear testament to our proactive global expansion strategy, aimed at significantly enhancing our research and development competitiveness on an international scale.”
She further elaborated, “By actively leveraging China’s outstanding talent pool and its rapidly advancing technological infrastructure, particularly within the Antibody-Drug Conjugate (ADC) sector, we are poised to significantly reinforce our capabilities in pioneering next-generation biopharmaceuticals.”
hwkan
